Kremer, J., Ritchlin, C., Mendelsohn, A., Baker, D., Kim, L., Xu, Z., . . . Taylor, P. (2010). Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Style de citation Chicago (17e éd.)Kremer, J., C. Ritchlin, A. Mendelsohn, D. Baker, L. Kim, Z. Xu, J. Han, et P. Taylor. Golimumab, a New Human Anti-tumor Necrosis Factor Alpha Antibody, Administered Intravenously in Patients with Active Rheumatoid Arthritis: Forty-eight-week Efficacy and Safety Results of a Phase III Randomized, Double-blind, Placebo-controlled Study. 2010.
Style de citation MLA (9e éd.)Kremer, J., et al. Golimumab, a New Human Anti-tumor Necrosis Factor Alpha Antibody, Administered Intravenously in Patients with Active Rheumatoid Arthritis: Forty-eight-week Efficacy and Safety Results of a Phase III Randomized, Double-blind, Placebo-controlled Study. 2010.